Estudio piloto de manifestaciones neurológicas en pacientes positivos para COVID-19 y Long COVID, y su relación con las variantes de los genes ACE2 (rs2074192 y rs879922) y APOE (rs429358 y rs7412) en un grupo de pacientes de Bogotá D.C.

dc.contributor.advisorArboleda Granados, Humbertospa
dc.contributor.advisorBernal Pacheco, Oscarspa
dc.contributor.authorBernal Castro, Hebert Jamesspa
dc.contributor.cvlacBernal Castro, Hebert James [0000007913#]spa
dc.contributor.researchgroupGrupo de Neurociencias-Universidad Nacional de Colombiaspa
dc.coverage.cityBogotáspa
dc.coverage.countryColombiaspa
dc.date.accessioned2024-09-10T17:49:41Z
dc.date.available2024-09-10T17:49:41Z
dc.date.issued2024
dc.descriptionilustraciones, diagramas, tablasspa
dc.description.abstractINTRODUCCIÓN: La pandemia de COVID-19, causada por el virus SARS-CoV-2, ha traído consigo no solo un desafío inmediato para la salud pública global, sino también una serie de manifestaciones clínicas de largo plazo conocidas como LONG COVID o secuelas posagudas de la infección por SARS-CoV-2 (PASC). Este síndrome multisistémico se caracteriza por una amplia gama de síntomas persistentes o emergentes que se extienden más allá de 4 semanas, ha generado una preocupación creciente en tanto la comunidad médica como en la población general. Además, su aparición es independiente a la severidad inicial de la infección, pero se observa en casos más graves y sigue siendo subdiagnosticada. La comprensión de la patogénesis del LONG COVID es aún incipiente. Entre los síntomas más debilitantes se encuentran las manifestaciones neurológicas y psiquiátricas, como la pérdida de memoria, el deterioro cognitivo y trastornos del estado del ánimo como ansiedad y depresión. Estudios recientes han sugerido similitudes entre las alteraciones cerebrales observadas con patologías neurodegenerativas. OBJETIVO: Identificar manifestaciones clínicas específicas asociadas con el LONG COVID, en particular los síntomas neurológicos y psiquiátricos, del COVID-19 y LONG COVID y su relación con las variantes de los genes ACE2 (rs2074192 y rs879922) y APOE (rs429358 y rs7412) en un grupo de pacientes de Bogotá D.C. Materiales y Métodos: Se realiza muestreo no probabilístico por conveniencia de 74 adultos residentes de Bogotá D.C., pareados por sexo y edad, para un estudio de casos y controles. Se realiza valoración médica, neuropsicológica al inicio y seguimiento de 6, 12 y 18 meses, con aplicación de pruebas cognitivas y afectivas. El genotipo de las variantes a estudiar se obtuvo mediante qPCR y sondas TaqMan. Resultados: En este estudio, el grupo de casos incluyó a 37 individuos con variada sintomatología de COVID-19 y LONG COVID, esta última con predominio de síntomas neurológicos, psiquiátricos y sistémicos, con pruebas cognitivas y afectivas mostrando alteraciones significativas comparadas al seguimiento y con el grupo control de 37 individuos. A pesar de que la frecuencia alélica de los polimorfismos de nucleótido único simple (SNPs) coincidió con bases de datos globales, no se halló una asociación directa con los síntomas de COVID-19 ni LONG COVID, ni con la aparición de estas dos entidades. Discusión: La relación entre la genética y las manifestaciones del COVID-19 y del LONG COVID, es compleja y no se encontró asociación entre los SNPs estudiados y los síntomas de la enfermedad. Los síntomas neurológicos y psiquiátricos persistentes sugieren que múltiples factores, tanto genéticos como ambientales, pueden estar involucrados en la respuesta individual al SARS-CoV-2, destacando la necesidad de una exploración más detallada de los mecanismos biológicos subyacentes (Texto tomado de la fuente).spa
dc.description.abstractIntroduction: The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has brought not only an immediate challenge to global public health but also a range of long-term clinical manifestations known as LONG COVID or post-acute sequelae of SARS-CoV-2 infection (PASC). This multisystemic syndrome, characterized by a wide range of persistent or emerging symptoms extending beyond 4 weeks, has raised increasing concern among both the medical community and the general population. Moreover, its occurrence is independent of the initial severity of the infection but is observed in more severe cases and remains underdiagnosed. Understanding the pathogenesis of LONG COVID is still in its early stages. Among the most debilitating symptoms are neurological and psychiatric manifestations, such as memory loss, cognitive impairment, and mood disorders like anxiety and depression. Recent studies have suggested similarities between the brain alterations observed with neurodegenerative pathologies. Objective: To identify specific clinical manifestations associated with LONG COVID, particularly neurological and psychiatric symptoms, of COVID-19 and LONG COVID and their relationship with variants of the ACE2 (rs2074192 and rs879922) and APOE (rs429358 and rs7412) genes in a group of patients from Bogotá D.C. Materials and Methods: A non-probabilistic convenience sampling of 74 adults residing in Bogotá D.C., matched by sex and age, was conducted for a case-control study. Medical and neuropsychological assessments were carried out at the start and follow-ups at 6, 12, and 18 months, with the application of cognitive and affective tests. The genotype of the variants under study was obtained using qPCR and TaqMan probes. Results: In this study, the case group included 37 individuals with varied symptoms of COVID-19 and LONG COVID, the latter predominated by neurological, psychiatric, and systemic symptoms, with cognitive and affective tests showing significant alterations compared to follow-up and the control group of 37 individuals. Although the allelic frequency of the single nucleotide polymorphisms (SNPs) matched global databases, no direct association was found with the symptoms of COVID-19 or LONG COVID, nor with the occurrence of these two entities. Discussion: The relationship between genetics and the manifestations of COVID-19 and LONG COVID is complex, and no association was found between the studied SNPs and the disease symptoms. Persistent neurological and psychiatric symptoms suggest that multiple factors, both genetic and environmental, may be involved in the individual response to SARS-CoV-2, highlighting the need for a more detailed exploration of the underlying biological mechanisms.eng
dc.description.degreelevelMaestríaspa
dc.description.degreenameMagíster en Neurocienciasspa
dc.description.methodsSe realiza estudio observacional de tipo analítico de cohorte para la caracterización clínica y genética, enfatizando aspectos neurológicos, cognitivos y afectivos, y de polimorfismos genéticos en un grupo de Casos y Controles. Se realiza muestreo no probabilístico por conveniencia de 74 individuos distribuidos equitativamente en grupos determinados por el estado de infección por SARS-CoV-2 (Grupo Casos) y la ausencia de la infección por SARS-CoV-2 (Grupo Control), pareados por edad y sexo. Además, el rango etario es entre 18 a 40 años. El tamaño de la muestra se estableció teniendo en cuenta las limitaciones inherentes de la pandemia, la viabilidad de la recolección de datos y las recomendaciones del tutor, en un contexto donde la incidencia del COVID-19 y la prevalencia de LONG COVID no estaban claramente definidas. Inicialmente se propuso 30 participantes por grupo, pero se ajustó a 37 por grupo debido a la disponibilidad de sujetos elegibles y mejorar la robustez del análisis estadístico. Aunque el tamaño de la muestra no se determinó mediante un cálculo de poder estadístico convencional, se buscó equilibrar la viabilidad práctica y la obtención de una cantidad de datos para realizar un análisis significativo. Además, se implementó un control de variables de confusión mediante el pareamiento por edad y sexo, añadiendo rigor metodológico al estudio. Para la organización del Grupo de casos, se establecieron subgrupos basados en los niveles de severidad descritos en los “LINEAMIENTOS PARA EL MANEJO CLÍNICO DE PACIENTES CON INFECCIÓN POR NUEVO CORONAVIRUS COVID-19”, proporcionados por el Ministerio de Salud y Protección Social de Colombia. No se incluyó el grado crítico, principalmente por las complejidades inherentes a la evaluación de pacientes en unidades de cuidados intensivos (UCI) y el síndrome post cuidados intensivos caracterizada por el deterioro físico, cognitivo y/o afectivo que aparece después de una enfermedad crítica y persiste tras el egreso hospitalariospa
dc.description.researchareaNeurocienciasspa
dc.format.extent123 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.instnameUniversidad Nacional de Colombiaspa
dc.identifier.reponameRepositorio Institucional Universidad Nacional de Colombiaspa
dc.identifier.repourlhttps://repositorio.unal.edu.co/spa
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/86817
dc.language.isospaspa
dc.publisherUniversidad Nacional de Colombiaspa
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotáspa
dc.publisher.facultyFacultad de Medicinaspa
dc.publisher.placeBogotá, Colombiaspa
dc.publisher.programBogotá - Medicina - Maestría en Neurocienciasspa
dc.relation.referencesRahman S, Montero MTV, Rowe K, Kirton R, Kunik F, Jr. Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence. Expert Rev Clin Pharmacol. 2021;14(5):601-21.spa
dc.relation.referencesRehman SU, Rehman SU, Yoo HH. COVID-19 challenges and its therapeutics. Biomed Pharmacother. 2021;142:112015.spa
dc.relation.referencesZhang HP, Sun YL, Wang YF, Yazici D, Azkur D, Ogulur I, et al. Recent developments in the immunopathology of COVID-19. Allergy. 2023;78(2):369-88.spa
dc.relation.referencesGuan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-20.spa
dc.relation.referencesJin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. 2020;12(4).spa
dc.relation.referencesSharma A, Ahmad Farouk I, Lal SK. COVID-19: A Review on the Novel Coronavirus Disease Evolution, Transmission, Detection, Control and Prevention. Viruses. 2021;13(2).spa
dc.relation.referencesFocosi D, Spezia PG, Maggi F. SARS-CoV-2 BA.2.86 ("Pirola"): Is it Pi or Just Another Omicron Sublineage? Vaccines (Basel). 2023;11(11).spa
dc.relation.referencesMeo SA, Meo AS, Klonoff DC. Omicron new variant BA.2.86 (Pirola): Epidemiological, biological, and clinical characteristics - a global data-based analysis. Eur Rev Med Pharmacol Sci. 2023;27(19):9470-6.spa
dc.relation.referencesLooi MK. Covid-19: WHO adds JN.1 as new variant of interest. BMJ. 2023;383:2975.spa
dc.relation.referencesScholkmann F, May CA. COVID-19, post-acute COVID-19 syndrome (PACS, "long COVID") and post-COVID-19 vaccination syndrome (PCVS, "post-COVIDvac-syndrome"): Similarities and differences. Pathol Res Pract. 2023;246:154497.spa
dc.relation.referencesThaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, et al. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. JAMA. 2023;329(22):1934-46.spa
dc.relation.referencesDavis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-46.spa
dc.relation.referencesBrannock MD, Chew RF, Preiss AJ, Hadley EC, Redfield S, McMurry JA, et al. Long COVID risk and pre-COVID vaccination in an EHR-based cohort study from the RECOVER program. Nat Commun. 2023;14(1):2914.spa
dc.relation.referencesKuodi P, Gorelik Y, Zayyad H, Wertheim O, Wiegler KB, Abu Jabal K, et al. Association between BNT162b2 vaccination and reported incidence of post-COVID-19 symptoms: cross-sectional study 2020-21, Israel. NPJ Vaccines. 2022;7(1):101.spa
dc.relation.referencesTang X, Wu C, Li X, Song Y, Yao X, Wu X, et al. On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev. 2020;7(6):1012-23.spa
dc.relation.referencesChen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-13.spa
dc.relation.referencesHu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141-54.spa
dc.relation.referencesWang L, Wang Y, Ye D, Liu Q. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. Int J Antimicrob Agents. 2020;55(6):105948.spa
dc.relation.referencesDu L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7(3):226-36.spa
dc.relation.referencesVijayanand P, Wilkins E, Woodhead M. Severe acute respiratory syndrome (SARS): a review. Clin Med (Lond). 2004;4(2):152-60.spa
dc.relation.referencesRamadan N, Shaib H. Middle East respiratory syndrome coronavirus (MERS-CoV): A review. Germs. 2019;9(1):35-42.spa
dc.relation.referencesChen H, Guan Y, Fan X. Animal reservoirs for SARS-like coronavirus in southern China. Hong Kong Med J. 2011;17 Suppl 6:36-40.spa
dc.relation.referencesDu L, Yang Y, Zhou Y, Lu L, Li F, Jiang S. MERS-CoV spike protein: a key target for antivirals. Expert Opin Ther Targets. 2017;21(2):131-43.spa
dc.relation.referencesPastrian-Soto G. Bases Genéticas y Moleculares del COVID-19 (SARS-CoV-2). Mecanismos de Patogénesis y de Respuesta Inmune. International journal of odontostomatology. 2020;14:331-7.spa
dc.relation.referencesLamers MM, Haagmans BL. SARS-CoV-2 pathogenesis. Nat Rev Microbiol. 2022;20(5):270-84.spa
dc.relation.referencesRastogi M, Pandey N, Shukla A, Singh SK. SARS coronavirus 2: from genome to infectome. Respir Res. 2020;21(1):318.spa
dc.relation.referencesBai C, Zhong Q, Gao GF. Overview of SARS-CoV-2 genome-encoded proteins. Sci China Life Sci. 2022;65(2):280-94.spa
dc.relation.referencesDhama K, Verma AK, Rajagunalan S, Deb R, Karthik K, Kapoor S, et al. Swine flu is back again: a review. Pak J Biol Sci. 2012;15(21):1001-9.spa
dc.relation.referencesDi Pierro F, Bertuccioli A, Cavecchia I. Possible therapeutic role of a highly standardized mixture of active compounds derived from cultured Lentinula edodes mycelia (AHCC) in patients infected with 2019 novel coronavirus. Minerva Gastroenterol Dietol. 2020;66(2):172-6.spa
dc.relation.referencesWrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260-3.spa
dc.relation.referencesGupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017-32.spa
dc.relation.referencesFirouzabadi N, Ghasemiyeh P, Moradishooli F, Mohammadi-Samani S. Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2. Int Immunopharmacol. 2023;117:109968.spa
dc.relation.referencesAraf Y, Akter F, Tang YD, Fatemi R, Parvez MSA, Zheng C, et al. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. J Med Virol. 2022;94(5):1825-32.spa
dc.relation.referencesZhou Y, Zhi H, Teng Y. The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity. J Med Virol. 2023;95(1):e28138.spa
dc.relation.referencesFlores-Vega VR, Monroy-Molina JV, Jimenez-Hernandez LE, Torres AG, Santos-Preciado JI, Rosales-Reyes R. SARS-CoV-2: Evolution and Emergence of New Viral Variants. Viruses. 2022;14(4).spa
dc.relation.referencesMuik A, Wallisch AK, Sanger B, Swanson KA, Muhl J, Chen W, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science. 2021;371(6534):1152-3.spa
dc.relation.referencesGiles B, Meredith P, Robson S, Smith G, Chauhan A, Pacific, et al. The SARS-CoV-2 B.1.1.7 variant and increased clinical severity-the jury is out. Lancet Infect Dis. 2021;21(9):1213-4.spa
dc.relation.referencesSanches PRS, Charlie-Silva I, Braz HLB, Bittar C, Freitas Calmon M, Rahal P, et al. Recent advances in SARS-CoV-2 Spike protein and RBD mutations comparison between new variants Alpha (B.1.1.7, United Kingdom), Beta (B.1.351, South Africa), Gamma (P.1, Brazil) and Delta (B.1.617.2, India). J Virus Erad. 2021;7(3):100054.spa
dc.relation.referencesTo KK, Sridhar S, Chiu KH, Hung DL, Li X, Hung IF, et al. Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. Emerg Microbes Infect. 2021;10(1):507-35.spa
dc.relation.referencesRanzani OT, Hitchings MDT, Dorion M, D'Agostini TL, de Paula RC, de Paula OFP, et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. BMJ. 2021;374:n2015.spa
dc.relation.referencesJia Z, Gong W. Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines? J Korean Med Sci. 2021;36(18):e124.spa
dc.relation.referencesDel Rio C, Malani PN, Omer SB. Confronting the Delta Variant of SARS-CoV-2, Summer 2021. JAMA. 2021;326(11):1001-2.spa
dc.relation.referencesDu Z, Xu X, Wu Y, Wang L, Cowling BJ, Meyers LA. Serial Interval of COVID-19 among Publicly Reported Confirmed Cases. Emerg Infect Dis. 2020;26(6):1341-3.spa
dc.relation.referencesLiu J, Huang J, Xiang D. Large SARS-CoV-2 Outbreak Caused by Asymptomatic Traveler, China. Emerg Infect Dis. 2020;26(9):2260-3.spa
dc.relation.referencesLi C, Ji F, Wang L, Wang L, Hao J, Dai M, et al. Asymptomatic and Human-to-Human Transmission of SARS-CoV-2 in a 2-Family Cluster, Xuzhou, China. Emerg Infect Dis. 2020;26(7):1626-8.spa
dc.relation.referencesSharma S, Jagadeesh H, Saxena A, Chakravarthy H, Devanathan V. Central nervous system as a target of novel coronavirus infections: Potential routes of entry and pathogenic mechanisms. J Biosci. 2021;46(4).spa
dc.relation.referencesZsichla L, Muller V. Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors. Viruses. 2023;15(1).spa
dc.relation.referencesGutierrez JP, Bertozzi SM. Non-communicable diseases and inequalities increase risk of death among COVID-19 patients in Mexico. PLoS One. 2020;15(10):e0240394.spa
dc.relation.referencesGao YD, Ding M, Dong X, Zhang JJ, Kursat Azkur A, Azkur D, et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021;76(2):428-55.spa
dc.relation.referencesGe E, Li Y, Wu S, Candido E, Wei X. Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: A population-based cohort study. PLoS One. 2021;16(10):e0258154.spa
dc.relation.referencesGandhi RT, Lynch JB, Del Rio C. Mild or Moderate Covid-19. N Engl J Med. 2020;383(18):1757-66.spa
dc.relation.referencesWeaver AK, Head JR, Gould CF, Carlton EJ, Remais JV. Environmental Factors Influencing COVID-19 Incidence and Severity. Annu Rev Public Health. 2022;43:271-91.spa
dc.relation.referencesBrooke GN, Prischi F. Structural and functional modelling of SARS-CoV-2 entry in animal models. Sci Rep. 2020;10(1):15917.spa
dc.relation.referencesWang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell. 2020;181(4):894-904 e9.spa
dc.relation.referencesMykytyn AZ, Breugem TI, Riesebosch S, Schipper D, van den Doel PB, Rottier RJ, et al. SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site. Elife. 2021;10.spa
dc.relation.referencesBeumer J, Geurts MH, Lamers MM, Puschhof J, Zhang J, van der Vaart J, et al. A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses. Nat Commun. 2021;12(1):5498.spa
dc.relation.referencesYin X, Riva L, Pu Y, Martin-Sancho L, Kanamune J, Yamamoto Y, et al. MDA5 Governs the Innate Immune Response to SARS-CoV-2 in Lung Epithelial Cells. Cell Rep. 2021;34(2):108628.spa
dc.relation.referencesYuan Y, Jiao B, Qu L, Yang D, Liu R. The development of COVID-19 treatment. Front Immunol. 2023;14:1125246.spa
dc.relation.referencesCastanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, Maertens de Noordhout C, et al. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. 2022;54(1):1473-87.spa
dc.relation.referencesLi F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005;309(5742):1864-8.spa
dc.relation.referencesPuelles VG, Lutgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, et al. Multiorgan and Renal Tropism of SARS-CoV-2. N Engl J Med. 2020;383(6):590-2.spa
dc.relation.referencesXiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. 2020;158(6):1831-3 e3.spa
dc.relation.referencesTavazzi G, Pellegrini C, Maurelli M, Belliato M, Sciutti F, Bottazzi A, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail. 2020;22(5):911-5.spa
dc.relation.referencesRoy D, Ghosh R, Dubey S, Dubey MJ, Benito-Leon J, Kanti Ray B. Neurological and Neuropsychiatric Impacts of COVID-19 Pandemic. Can J Neurol Sci. 2021;48(1):9-24.spa
dc.relation.referencesSadowski J, Klaudel T, Rombel-Bryzek A, Buldak RJ. Cognitive dysfunctions in the course of SARS‑CoV‑2 virus infection, including NeuroCOVID, frontal syndrome and cytokine storm (Review). Biomed Rep. 2024;21(1):103.spa
dc.relation.referencesHewitt KC, Marra DE, Block C, Cysique LA, Drane DL, Haddad MM, et al. Central Nervous System Manifestations of COVID-19: A Critical Review and Proposed Research Agenda. J Int Neuropsychol Soc. 2022;28(3):311-25.spa
dc.relation.referencesRamani A, Muller L, Ostermann PN, Gabriel E, Abida-Islam P, Muller-Schiffmann A, et al. SARS-CoV-2 targets neurons of 3D human brain organoids. EMBO J. 2020;39(20):e106230.spa
dc.relation.referencesMoriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis. 2020;94:55-8.spa
dc.relation.referencesSudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626-31.spa
dc.relation.referencesSoriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, Condition WHOCCDWGoP-C-. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102-e7.spa
dc.relation.referencesSivan M, Taylor S. NICE guideline on long covid. BMJ. 2020;371:m4938spa
dc.relation.referencesMunblit D, O'Hara ME, Akrami A, Perego E, Olliaro P, Needham DM. Long COVID: aiming for a consensus. Lancet Respir Med. 2022;10(7):632-4.spa
dc.relation.referencesKozłowski P, Leszczyńska A, Ciepiela O. Long COVID Definition, Symptoms, Risk Factors, Epidemiology and Autoimmunity: A Narrative Review. American Journal of Medicine Open. 2024;11:100068.spa
dc.relation.referencesLopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11(1):16144.spa
dc.relation.referencesTran VT, Porcher R, Pane I, Ravaud P. Course of post COVID-19 disease symptoms over time in the ComPaRe long COVID prospective e-cohort. Nat Commun. 2022;13(1):1812.spa
dc.relation.referencesKim Y, Bae S, Chang HH, Kim SW. Characteristics of long COVID and the impact of COVID-19 vaccination on long COVID 2 years following COVID-19 infection: prospective cohort study. Sci Rep. 2024;14(1):854.spa
dc.relation.referencesLopez-Sampalo A, Bernal-Lopez MR, Gomez-Huelgas R. [Persistent COVID-19 syndrome. A narrative review]. Rev Clin Esp. 2022;222(4):241-50.spa
dc.relation.referencesBello-Chavolla OY, Fermin-Martinez CA, Ramirez-Garcia D, Vargas-Vazquez A, Fernandez-Chirino L, Basile-Alvarez MR, et al. Prevalence and determinants of post-acute sequelae after SARS-CoV-2 infection (Long COVID) among adults in Mexico during 2022: a retrospective analysis of nationally representative data. Lancet Reg Health Am. 2024;30:100688.spa
dc.relation.referencesRighi E, Mirandola M, Mazzaferri F, Dossi G, Razzaboni E, Zaffagnini A, et al. Determinants of persistence of symptoms and impact on physical and mental wellbeing in Long COVID: A prospective cohort study. J Infect. 2022;84(4):566-72.spa
dc.relation.referencesHalpin S, O'Connor R, Sivan M. Long COVID and chronic COVID syndromes. J Med Virol. 2021;93(3):1242-3.spa
dc.relation.referencesHuang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220-32.spa
dc.relation.referencesBoglione L, Meli G, Poletti F, Rostagno R, Moglia R, Cantone M, et al. Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect? QJM. 2022;114(12):865-71.spa
dc.relation.referencesDurstenfeld MS, Peluso MJ, Peyser ND, Lin F, Knight SJ, Djibo A, et al. Factors Associated with Long Covid Symptoms in an Online Cohort Study. medRxiv. 2022.spa
dc.relation.referencesNasserie T, Hittle M, Goodman SN. Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review. JAMA Netw Open. 2021;4(5):e2111417.spa
dc.relation.referencesFord ND, Slaughter D, Edwards D, Dalton A, Perrine C, Vahratian A, et al. Long COVID and Significant Activity Limitation Among Adults, by Age - United States, June 1-13, 2022, to June 7-19, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(32):866-70.spa
dc.relation.referencesAngarita-Fonseca A, Torres-Castro R, Benavides-Cordoba V, Chero S, Morales-Satan M, Hernandez-Lopez B, et al. Exploring long COVID condition in Latin America: Its impact on patients' activities and associated healthcare use. Front Med (Lausanne). 2023;10:1168628.spa
dc.relation.referencesLapa J, Rosa D, Mendes JPL, Deusdara R, Romero GAS. Prevalence and Associated Factors of Post-COVID-19 Syndrome in a Brazilian Cohort after 3 and 6 Months of Hospital Discharge. Int J Environ Res Public Health. 2023;20(1).spa
dc.relation.referencesYong SJ, Liu S. Proposed subtypes of post-COVID-19 syndrome (or long-COVID) and their respective potential therapies. Rev Med Virol. 2022;32(4):e2315.spa
dc.relation.referencesLiew F, Efstathiou C, Fontanella S, Richardson M, Saunders R, Swieboda D, et al. Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease. Nat Immunol. 2024;25(4):607-21.spa
dc.relation.referencesCysique LA, Jakabek D, Bracken SG, Allen-Davidian Y, Heng B, Chow S, et al. The kynurenine pathway relates to post-acute COVID-19 objective cognitive impairment and PASC. Ann Clin Transl Neurol. 2023;10(8):1338-52.spa
dc.relation.referencesConstantinescu-Bercu A, Lobiuc A, Caliman-Sturdza OA, Oita RC, Iavorschi M, Paval NE, et al. Long COVID: Molecular Mechanisms and Detection Techniques. Int J Mol Sci. 2023;25(1).spa
dc.relation.referencesKim JE, Heo JH, Kim HO, Song SH, Park SS, Park TH, et al. Neurological Complications during Treatment of Middle East Respiratory Syndrome. J Clin Neurol. 2017;13(3):227-33.spa
dc.relation.referencesPalaiodimou L, Stefanou MI, Katsanos AH, Fragkou PC, Papadopoulou M, Moschovos C, et al. Prevalence, clinical characteristics and outcomes of Guillain-Barre syndrome spectrum associated with COVID-19: A systematic review and meta-analysis. Eur J Neurol. 2021;28(10):3517-29.spa
dc.relation.referencesFilosto M, Cotti Piccinelli S, Gazzina S, Foresti C, Frigeni B, Servalli MC, et al. Guillain-Barre syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions. J Neurol Neurosurg Psychiatry. 2021;92(7):751-6.spa
dc.relation.referencesSwank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, et al. Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae. Clin Infect Dis. 2023;76(3):e487-e90spa
dc.relation.referencesProal AD, VanElzakker MB. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. Front Microbiol. 2021;12:698169.spa
dc.relation.referencesZubchenko S, Kril I, Nadizhko O, Matsyura O, Chopyak V. Herpesvirus infections and post-COVID-19 manifestations: a pilot observational study. Rheumatol Int. 2022;42(9):1523-30.spa
dc.relation.referencesYeoh YK, Zuo T, Lui GC, Zhang F, Liu Q, Li AY, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021;70(4):698-706.spa
dc.relation.referencesArthur JM, Forrest JC, Boehme KW, Kennedy JL, Owens S, Herzog C, et al. Development of ACE2 autoantibodies after SARS-CoV-2 infection. PLoS One. 2021;16(9):e0257016.spa
dc.relation.referencesPretorius E, Venter C, Laubscher GJ, Kotze MJ, Oladejo SO, Watson LR, et al. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC). Cardiovasc Diabetol. 2022;21(1):148.spa
dc.relation.referencesSpudich S, Nath A. Nervous system consequences of COVID-19. Science. 2022;375(6578):267-9.spa
dc.relation.referencesFernandez-Castaneda A, Lu P, Geraghty AC, Song E, Lee MH, Wood J, et al. Mild respiratory SARS-CoV-2 infection can cause multi-lineage cellular dysregulation and myelin loss in the brain. bioRxiv. 2022.spa
dc.relation.referencesFrere JJ, Serafini RA, Pryce KD, Zazhytska M, Oishi K, Golynker I, et al. SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations after recovery. Sci Transl Med. 2022;14(664):eabq3059.spa
dc.relation.referencesCrook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374:n1648.spa
dc.relation.referencesWrenn JO, Pakala SB, Vestal G, Shilts MH, Brown HM, Bowen SM, et al. COVID-19 severity from Omicron and Delta SARS-CoV-2 variants. Influenza Other Respir Viruses. 2022;16(5):832-6.spa
dc.relation.referencesFernandez-de-Las-Penas C, Cancela-Cilleruelo I, Rodriguez-Jimenez J, Gomez-Mayordomo V, Pellicer-Valero OJ, Martin-Guerrero JD, et al. Associated-Onset Symptoms and Post-COVID-19 Symptoms in Hospitalized COVID-19 Survivors Infected with Wuhan, Alpha or Delta SARS-CoV-2 Variant. Pathogens. 2022;11(7).spa
dc.relation.referencesDu M, Ma Y, Deng J, Liu M, Liu J. Comparison of Long COVID-19 Caused by Different SARS-CoV-2 Strains: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2022;19(23).spa
dc.relation.referencesGupta K, Kaur G, Pathak T, Banerjee I. Systematic review and meta-analysis of human genetic variants contributing to COVID-19 susceptibility and severity. Gene. 2022;844:146790.spa
dc.relation.referencesPecoraro V, Cuccorese M, Trenti T. Genetic polymorphisms of ACE1, ACE2, IFTM3, TMPRSS2 and TNFalpha genes associated with susceptibility and severity of SARS-CoV-2 infection: a systematic review and meta-analysis. Clin Exp Med. 2023;23(7):3251-64.spa
dc.relation.referencesSaengsiwaritt W, Jittikoon J, Chaikledkaew U, Udomsinprasert W. Genetic polymorphisms of ACE1, ACE2, and TMPRSS2 associated with COVID-19 severity: A systematic review with meta-analysis. Rev Med Virol. 2022;32(4):e2323.spa
dc.relation.referencesVarillas-Delgado D, Jimenez-Antona C, Lizcano-Alvarez A, Cano-de-la-Cuerda R, Molero-Sanchez A, Laguarta-Val S. Predictive Factors and ACE-2 Gene Polymorphisms in Susceptibility to Long COVID-19 Syndrome. Int J Mol Sci. 2023;24(23).spa
dc.relation.referencesAngulo-Aguado M, Corredor-Orlandelli D, Carrillo-Martinez JC, Gonzalez-Cornejo M, Pineda-Mateus E, Rojas C, et al. Association Between the LZTFL1 rs11385942 Polymorphism and COVID-19 Severity in Colombian Population. Front Med (Lausanne). 2022;9:910098.spa
dc.relation.referencesAngulo-Aguado M, Carrillo-Martinez JC, Contreras-Bravo NC, Morel A, Parra-Abaunza K, Usaquen W, et al. Next-generation sequencing of host genetics risk factors associated with COVID-19 severity and long-COVID in Colombian population. Sci Rep. 2024;14(1):8497.spa
dc.relation.referencesMartinez-Gomez LE, Herrera-Lopez B, Martinez-Armenta C, Ortega-Pena S, Camacho-Rea MDC, Suarez-Ahedo C, et al. ACE and ACE2 Gene Variants Are Associated With Severe Outcomes of COVID-19 in Men. Front Immunol. 2022;13:812940.spa
dc.relation.referencesOchoa-Ramirez LA, Corona-Angulo AL, Rios-Burgueno ER, Sanchez-Zazueta JG, Becerra-Loaiza DS, Velarde-Felix JS. Vitamin D receptor gene polymorphisms role in COVID-19 severity: Results of a Mexican patients' cohort. Int J Immunogenet. 2024.spa
dc.relation.referencesChavez-Velez E, Alvarez-Nava F, Torres-Vinueza A, Balarezo-Diaz T, Pilataxi K, Acosta-Lopez C, et al. Single nucleotide variants in the CCL2, OAS1 and DPP9 genes and their association with the severity of COVID-19 in an Ecuadorian population. Front Cell Infect Microbiol. 2024;14:1322882.spa
dc.relation.referencesde Araujo JLF, Bonifacio VF, Batista LM, de Avila RE, Aguiar RS, Bastos-Rodrigues L, et al. Association of 3p21.31 Locus (CXCR6 and LZTFL1) with COVID-19 Outcomes in Brazilian Hospitalyzed Subjects. Curr Microbiol. 2023;80(10):319spa
dc.relation.referencesde Andrade CC, Silva ATP, Vasconcelos LRS, Oliveira PRS, de Souza CDF, da Costa Armstrong A, et al. A Polymorphism in the TMPRSS2 Gene Increases the Risk of Death in Older Patients Hospitalized with COVID-19. Viruses. 2022;14(11).spa
dc.relation.referencesMicheletti C, Medori MC, Dhuli K, Maltese PE, Cecchin S, Bonetti G, et al. Linking pathogenic and likely pathogenic gene variants to long-COVID symptoms. Eur Rev Med Pharmacol Sci. 2023;27(6 Suppl):20-32.spa
dc.relation.referencesUdomsinprasert W, Nontawong N, Saengsiwaritt W, Panthan B, Jiaranai P, Thongchompoo N, et al. Host genetic polymorphisms involved in long-term symptoms of COVID-19. Emerg Microbes Infect. 2023;12(2):2239952.spa
dc.relation.referencesTavares-Junior JWL, Oliveira DN, da Silva JBS, Feitosa WLQ, Sousa AVM, Cunha LCV, et al. Long-covid cognitive impairment: Cognitive assessment and apolipoprotein E (APOE) genotyping correlation in a Brazilian cohort. Front Psychiatry. 2022;13:947583.spa
dc.relation.referencesFernandez-de-Las-Penas C, Arendt-Nielsen L, Diaz-Gil G, Gomez-Esquer F, Gil-Crujera A, Gomez-Sanchez SM, et al. Genetic Association between ACE2 (rs2285666 and rs2074192) and TMPRSS2 (rs12329760 and rs2070788) Polymorphisms with Post-COVID Symptoms in Previously Hospitalized COVID-19 Survivors. Genes (Basel). 2022;13(11).spa
dc.relation.referencesHikmet F, Mear L, Edvinsson A, Micke P, Uhlen M, Lindskog C. The protein expression profile of ACE2 in human tissues. Mol Syst Biol. 2020;16(7):e9610.spa
dc.relation.referencesLv Y, Li Y, Yi Y, Zhang L, Shi Q, Yang J. A Genomic Survey of Angiotensin-Converting Enzymes Provides Novel Insights into Their Molecular Evolution in Vertebrates. Molecules. 2018;23(11).spa
dc.relation.referencesChen R, Wang K, Yu J, Howard D, French L, Chen Z, et al. The Spatial and Cell-Type Distribution of SARS-CoV-2 Receptor ACE2 in the Human and Mouse Brains. Front Neurol. 2020;11:573095.spa
dc.relation.referencesBunyavanich S, Do A, Vicencio A. Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults. JAMA. 2020;323(23):2427-9.spa
dc.relation.referencesDonoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87(5):E1-9.spa
dc.relation.referencesChamsi-Pasha MA, Shao Z, Tang WH. Angiotensin-converting enzyme 2 as a therapeutic target for heart failure. Curr Heart Fail Rep. 2014;11(1):58-63.spa
dc.relation.referencesBelloy ME, Napolioni V, Greicius MD. A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward. Neuron. 2019;101(5):820-38.spa
dc.relation.referencesHerz J, Beffert U. Apolipoprotein E receptors: linking brain development and Alzheimer's disease. Nat Rev Neurosci. 2000;1(1):51-8.spa
dc.relation.referencesForero DA, Casadesus G, Perry G, Arboleda H. Synaptic dysfunction and oxidative stress in Alzheimer's disease: emerging mechanisms. J Cell Mol Med. 2006;10(3):796-805.spa
dc.relation.referencesEisenberg DT, Kuzawa CW, Hayes MG. Worldwide allele frequencies of the human apolipoprotein E gene: climate, local adaptations, and evolutionary history. Am J Phys Anthropol. 2010;143(1):100-11.spa
dc.relation.referencesMunoz SS, Garner B, Ooi L. Understanding the Role of ApoE Fragments in Alzheimer's Disease. Neurochem Res. 2019;44(6):1297-305.spa
dc.relation.referencesMorrow JA, Segall ML, Lund-Katz S, Phillips MC, Knapp M, Rupp B, et al. Differences in stability among the human apolipoprotein E isoforms determined by the amino-terminal domain. Biochemistry. 2000;39(38):11657-66.spa
dc.relation.referencesDieter C, Brondani LA, Leitao CB, Gerchman F, Lemos NE, Crispim D. Genetic polymorphisms associated with susceptibility to COVID-19 disease and severity: A systematic review and meta-analysis. PLoS One. 2022;17(7):e0270627spa
dc.relation.referencesChen F, Chen Y, Ke Q, Wang Y, Gong Z, Chen X, et al. ApoE4 associated with severe COVID-19 outcomes via downregulation of ACE2 and imbalanced RAS pathway. J Transl Med. 2023;21(1):103spa
dc.relation.referencesKurki SN, Kantonen J, Kaivola K, Hokkanen L, Mayranpaa MI, Puttonen H, et al. APOE epsilon4 associates with increased risk of severe COVID-19, cerebral microhaemorrhages and post-COVID mental fatigue: a Finnish biobank, autopsy and clinical study. Acta Neuropathol Commun. 2021;9(1):199.spa
dc.relation.referencesKuo CL, Pilling LC, Atkins JL, Masoli JAH, Delgado J, Kuchel GA, et al. ApoE e4e4 Genotype and Mortality With COVID-19 in UK Biobank. J Gerontol A Biol Sci Med Sci. 2020;75(9):1801-3.spa
dc.relation.referencesWang C, Zhang M, Garcia G, Jr., Tian E, Cui Q, Chen X, et al. ApoE-Isoform-Dependent SARS-CoV-2 Neurotropism and Cellular Response. Cell Stem Cell. 2021;28(2):331-42 e5.spa
dc.relation.referencesMonteiro-Junior RS. COVID-19: Thinking about further mental and neurological disorders. Med Hypotheses. 2020;143:109894.spa
dc.relation.referencesZhang H, Shao L, Lin Z, Long QX, Yuan H, Cai L, et al. APOE interacts with ACE2 inhibiting SARS-CoV-2 cellular entry and inflammation in COVID-19 patients. Signal Transduct Target Ther. 2022;7(1):261.spa
dc.relation.referencesSantos RAS, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M, et al. The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). Physiol Rev. 2018;98(1):505-53.spa
dc.relation.referencesSamavati L, Uhal BD. ACE2, Much More Than Just a Receptor for SARS-COV-2. Front Cell Infect Microbiol. 2020;10:317.spa
dc.relation.referencesFernandez-de-Las-Penas C, Arendt-Nielsen L, Diaz-Gil G, Gomez-Esquer F, Gil-Crujera A, Gomez-Sanchez SM, et al. Apolipoprotein E (ApoE) epsilon4 Genotype (ApoE rs429358-ApoE rs7412 Polymorphisms) Is Not Associated with Long COVID Symptoms in Previously Hospitalized COVID-19 Survivors. Genes (Basel). 2023;14(7).spa
dc.relation.referencesTavares-Junior JWL, Oliveira DN, da Silva JBS, Queiroz Feitosa WL, Sousa AVM, Marinho SC, et al. Post-COVID-19 Cognitive Decline and Apoe Polymorphism: Towards a Possible Link? Brain Sci. 2023;13(12).spa
dc.relation.referencesGomez F, Zunzunegui M, Lord C, Alvarado B, Garcia A. Applicability of the MoCA-S test in populations with little education in Colombia. Int J Geriatr Psychiatry. 2013;28(8):813-20.spa
dc.relation.referencesJulian LJ. Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A). Arthritis Care Res (Hoboken). 2011;63 Suppl 11(0 11):S467-72.spa
dc.relation.referencesGonzalez DA, Resendiz A, Reyes-Lagunes I. Adaptation of the BDI-II in Mexico. Salud Ment (Mex). 2015;38(4):237-44.spa
dc.relation.referencesDavis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019.spa
dc.relation.referencesPedrozo-Pupo JC, Caballero-Dominguez CC, Campo-Arias A. Prevalence and variables associated with insomnia among COVID-19 survivors in Colombia. Acta Biomed. 2022;93(1):e2022019.spa
dc.relation.referencesCampo-Arias A, Pedrozo-Pupo JC, Caballero-Dominguez CC. Relation of perceived discrimination with depression, insomnia and post-traumatic stress in COVID-19 survivors. Psychiatry Res. 2022;307:114337.spa
dc.relation.referencesQuiroga SA, Hernandez C, Castaneda S, Jimenez P, Vega L, Gomez M, et al. Contrasting SARS-CoV-2 RNA copies and clinical symptoms in a large cohort of Colombian patients during the first wave of the COVID-19 pandemic. Ann Clin Microbiol Antimicrob. 2021;20(1):39.spa
dc.relation.referencesCaballero-Dominguez CC, Pedrozo-Pupo JC, Campo-Arias A. Depression among COVID-19 survivors in Colombia. Psychol Health Med. 2023;28(6):1495-502.spa
dc.relation.referencesCrivelli L, Palmer K, Calandri I, Guekht A, Beghi E, Carroll W, et al. Changes in cognitive functioning after COVID-19: A systematic review and meta-analysis. Alzheimers Dement. 2022;18(5):1047-66.spa
dc.relation.referencesPerrottelli A, Sansone N, Giordano GM, Caporusso E, Giuliani L, Melillo A, et al. Cognitive Impairment after Post-Acute COVID-19 Infection: A Systematic Review of the Literature. J Pers Med. 2022;12(12).spa
dc.relation.referencesCipolli GC, Alonso V, Yasuda CL, Assumpcao D, Cachioni M, Melo RC, et al. Cognitive impairment in post-acute COVID-19 syndrome: a scoping review. Arq Neuropsiquiatr. 2023;81(12):1053-69.spa
dc.relation.referencesBertuccelli M, Ciringione L, Rubega M, Bisiacchi P, Masiero S, Del Felice A. Cognitive impairment in people with previous COVID-19 infection: A scoping review. Cortex. 2022;154:212-30.spa
dc.relation.referencesRan S, Yao J, Liu B. The association between COVID-19 and cognitive performance: A Mendelian randomization analysis. Alzheimers Dement. 2023;19(6):2742-4.spa
dc.relation.referencesKozik V, Reuken P, Utech I, Gramlich J, Stallmach Z, Demeyere N, et al. Characterization of neurocognitive deficits in patients with post-COVID-19 syndrome: persistence, patients' complaints, and clinical predictors. Front Psychol. 2023;14:1233144spa
dc.relation.referencesBiagianti B, Di Liberto A, Nicolo Edoardo A, Lisi I, Nobilia L, de Ferrabonc GD, et al. Cognitive Assessment in SARS-CoV-2 Patients: A Systematic Review. Front Aging Neurosci. 2022;14:909661.spa
dc.relation.referencesZawilska JB, Kuczynska K. Psychiatric and neurological complications of long COVID. J Psychiatr Res. 2022;156:349-60.spa
dc.relation.referencesLeitner M, Potz G, Berger M, Fellner M, Spat S, Koini M. Characteristics and burden of acute COVID-19 and long-COVID: Demographic, physical, mental health, and economic perspectives. PLoS One. 2024;19(1):e0297207.spa
dc.relation.referencesHawes MT, Szenczy AK, Klein DN, Hajcak G, Nelson BD. Increases in depression and anxiety symptoms in adolescents and young adults during the COVID-19 pandemic. Psychol Med. 2022;52(14):3222-30.spa
dc.relation.referencesMazza MG, Palladini M, Poletti S, Benedetti F. Post-COVID-19 Depressive Symptoms: Epidemiology, Pathophysiology, and Pharmacological Treatment. CNS Drugs. 2022;36(7):681-702.spa
dc.relation.referencesBota AV, Bratosin F, Bogdan I, Septimiu-Radu S, Ilie AC, Burtic SR, et al. Assessing the Quality of Life, Coping Strategies, Anxiety and Depression Levels in Patients with Long-COVID-19 Syndrome: A Six-Month Follow-Up Study. Diseases. 2024;12(1).spa
dc.relation.referencesBourmistrova NW, Solomon T, Braude P, Strawbridge R, Carter B. Long-term effects of COVID-19 on mental health: A systematic review. J Affect Disord. 2022;299:118-25.spa
dc.relation.referencesFan Z, Wu G, Yue M, Ye J, Chen Y, Xu B, et al. Hypertension and hypertensive left ventricular hypertrophy are associated with ACE2 genetic polymorphism. Life Sci. 2019;225:39-45.spa
dc.relation.referencesPan Y, Wang T, Li Y, Guan T, Lai Y, Shen Y, et al. Association of ACE2 polymorphisms with susceptibility to essential hypertension and dyslipidemia in Xinjiang, China. Lipids Health Dis. 2018;17(1):241.spa
dc.relation.referencesHuang G, Wang Y, Qin L, Huang B, Yu X. Association and functional analysis of angiotensin-converting enzyme 2 genetic variants with the pathogenesis of pre-eclampsia. Front Endocrinol (Lausanne). 2022;13:926512.spa
dc.relation.referencesLiu C, Li Y, Guan T, Lai Y, Shen Y, Zeyaweiding A, et al. ACE2 polymorphisms associated with cardiovascular risk in Uygurs with type 2 diabetes mellitus. Cardiovasc Diabetol. 2018;17(1):127.spa
dc.relation.referencesLumpuy-Castillo J, Vales-Villamarin C, Mahillo-Fernandez I, Perez-Nadador I, Soriano-Guillen L, Lorenzo O, et al. Association of ACE2 Polymorphisms and Derived Haplotypes With Obesity and Hyperlipidemia in Female Spanish Adolescents. Front Cardiovasc Med. 2022;9:888830.spa
dc.relation.referencesJalaleddine N, Bouzid A, Hachim M, Sharif-Askari NS, Mahboub B, Senok A, et al. ACE2 polymorphisms impact COVID-19 severity in obese patients. Sci Rep. 2022;12(1):21491.spa
dc.relation.referencesSong W, Wang H, Ma L, Chen Y. Associations between the TNMD rs4828038 and ACE2 rs879922 polymorphisms and preeclampsia susceptibility: a case-control study. J Obstet Gynaecol. 2022;42(5):1132-6.spa
dc.relation.referencesBosso M, Thanaraj TA, Abu-Farha M, Alanbaei M, Abubaker J, Al-Mulla F. The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19. Mol Ther Methods Clin Dev. 2020;18:321-7.spa
dc.relation.referencesSheikhian F, Sadeghi Mofrad S, Tarashi S, Ghazanfari Jajin M, Sakhaee F, Ahmadi I, et al. The impact of ACE2 polymorphisms (rs1978124, rs2285666, and rs2074192) and ACE1 rs1799752 in the mortality rate of COVID-19 in different SARS-CoV-2 variants. Hum Genomics. 2023;17(1):54.spa
dc.relation.referencesHamet P, Pausova Z, Attaoua R, Hishmih C, Haloui M, Shin J, et al. SARS-CoV-2 Receptor ACE2 Gene Is Associated with Hypertension and Severity of COVID 19: Interaction with Sex, Obesity, and Smoking. Am J Hypertens. 2021;34(4):367-76spa
dc.relation.referencesFaustine I, Marteka D, Malik A, Supriyanto E, Syafhan NF. Genotype variation of ACE and ACE2 genes affects the severity of COVID-19 patients. BMC Res Notes. 2023;16(1):194.spa
dc.relation.referencesKuo CL, Pilling LC, Atkins JL, Masoli JAH, Delgado J, Kuchel GA, et al. APOE e4 Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort. J Gerontol A Biol Sci Med Sci. 2020;75(11):2231-2.spa
dc.relation.referencesChen F, Ke Q, Wei W, Cui L, Wang Y. Apolipoprotein E and viral infection: Risks and Mechanisms. Mol Ther Nucleic Acids. 2023;33:529-42.spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.licenseAtribución-NoComercial 4.0 Internacionalspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/spa
dc.subject.ddc610 - Medicina y salud::616 - Enfermedadesspa
dc.subject.ddc610 - Medicina y salud::613 - Salud y seguridad personalspa
dc.subject.decsInsuficiencia Multiorgánicaspa
dc.subject.decsMultiple Organ Failureeng
dc.subject.decsSíndrome Post Agudo de COVID-19spa
dc.subject.decsPost-Acute COVID-19 Syndromeeng
dc.subject.decsManifestaciones Neurológicasspa
dc.subject.decsDisfunción Cognitivaspa
dc.subject.decsCognitive Dysfunctioneng
dc.subject.decsNeurologic Manifestationseng
dc.subject.lembINFECCIONES POR CORONAVIRUSspa
dc.subject.lembCoronavirus infectionseng
dc.subject.proposalCovid-19spa
dc.subject.proposalLong Covidspa
dc.subject.proposalSalud Mentalspa
dc.subject.proposalCogniciónspa
dc.subject.proposalACE2spa
dc.subject.proposalAPOEspa
dc.subject.proposalMental Healtheng
dc.subject.proposalCognitioneng
dc.titleEstudio piloto de manifestaciones neurológicas en pacientes positivos para COVID-19 y Long COVID, y su relación con las variantes de los genes ACE2 (rs2074192 y rs879922) y APOE (rs429358 y rs7412) en un grupo de pacientes de Bogotá D.C.spa
dc.title.translatedPilot study of neurological manifestations in COVID-19 positive and Long COVID patients, and their relationship with variants of the ACE2 (rs2074192 and rs879922) and APOE (rs429358 and rs7412) genes in a group of patients from Bogotá D.C.eng
dc.typeTrabajo de grado - Maestríaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdccspa
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/masterThesisspa
dc.type.redcolhttp://purl.org/redcol/resource_type/TMspa
dc.type.versioninfo:eu-repo/semantics/acceptedVersionspa
dcterms.audience.professionaldevelopmentEstudiantesspa
dcterms.audience.professionaldevelopmentInvestigadoresspa
dcterms.audience.professionaldevelopmentMaestrosspa
dcterms.audience.professionaldevelopmentPúblico generalspa
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2spa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
1018459407.2024.pdf
Tamaño:
2.65 MB
Formato:
Adobe Portable Document Format
Descripción:
Tesis de Maestría en Neurociencias

Bloque de licencias

Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
5.74 KB
Formato:
Item-specific license agreed upon to submission
Descripción: